==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1014 which contains 12 entries.


Entry 1
(1) Primary information
ID1098
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesBone Density Conservation Agents
Patents NumberUS6440392
Date of Issue02/02/01
Date of Expiry02/02/21
Drug InteractionEskalith (lithium)
TargetCalcitonin receptor
Information of corresponding available drug in the market
Brand NameCalcimar
CompanyN.A.
Brand DiscriptionCalcitonin is a group of polypeptide hormones secreted by the thyroid gland in mammals and by the ultimobranchial gland of birds and fish. It is of physiological importance in the regulation of calcium metabolism in certain animal species, and may also ha
Prescribed forTo treat Paget's disease of bone
Chemical NameN.A.
FormulationEach mL of sterile solution contains calcitonin salmon 200 IU. Nonmedicinal ingredients include acetic acid, phenol, sodium acetate, sodium chloride, sodium hydroxide and water for injection.
Physcial AppearanceSolution
Route of AdministrationSubcutaneous or intramuSubcutaneousular Injection
Recommended DosageBased on body weight and injected every 12 hours
ContraindicationAllergy
Side EffectsFeeling light-headed, fainting; or muscle stiffness.
Useful Linkhttp://www.drugs.com/sfx/calcimar-side-effects.html
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 2
(2) Primary information
ID1099
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesAntihypercalcemic Agents
Patents NumberUS5733569
Date of Issue31/03/95
Date of Expiry31/03/15
Drug InteractionEskalith-CR (lithium)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forFor treatment of postmenopausal osteoporosis
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsSwelling in your feet
Useful Linkhttp://www.drugs.com/drug-interactions/calcitonin-index.html?filter=1
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 3
(3) Primary information
ID1100
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesAnti-Osteporotic Agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionFoscavir (foscarnet)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forTo reduce high levels of calcium in the blood (hypercalcemia)
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsSwelling or irritation of the skin where an injection was given.
Useful Linkhttp://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs/CPS-%20Monographs/CPS-%20%28General%20Monographs-%20C%29/CALCIMAR.html
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 4
(4) Primary information
ID1101
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionLithium Carbonate ER (lithium)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsWarmth, redness, itching, or tingly feeling under your skin; nausea, loss of appetite, stomach pain
Useful LinkN.A.
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 5
(5) Primary information
ID1102
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionLithobid (lithium)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsVomiting; skin rash or itching; increased urination, especially at night; eye pain
Useful LinkN.A.
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 6
(6) Primary information
ID1103
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionLithonate (lithium)
TargetN.A.
Information of corresponding available drug in the market
Brand NameFortical
CompanyN.A.
Brand DiscriptionThe active ingredient of 32 amino acids in Fortical (calcitonin-salmon of rDNA origin) nasal spray is a polypeptide manufactured by recombinant DNA technology
Prescribed forUsed to treat osteoporosis in women who have been in menopause for at least 5 years. To be used along with adequate calcium and vitamin D intake.
Chemical NameN.A.
FormulationCalcitonin-salmon 2200 International Units/mL, corresponding to 200 International Units per actuation (0.09 mL) and Sodium Chloride, Citric Acid, Phenylethyl Alcohol, Benzyl Alcohol, Polysorbate 80, Hydrochloric Acid or Sodium Hydroxide (added as necess
Physcial AppearanceNasal spray
Route of AdministrationIntranasal use
Recommended DosageEach spray delivers 200 International Units calcitonin-salmon in a volume of 0.09 mL.
ContraindicationAllergy
Side EffectsTremors or shaking, feeling like you might pass out, severe nasal irritation.
Useful Linkhttp://www.drugs.com/fortical.html
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 7
(7) Primary information
ID1104
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionLithotabs (lithium)
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsBleeding from your nose, runny or stuffy nose, dryness, itching, tenderness, or general discomfort of your nose, crusting, scabs, or sores inside your nose, redness in or around your nose.
Useful Linkhttp://www.drugs.com/drug-interactions/calcitonin,fortical-index.html?filter=1
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 8
(8) Primary information
ID1105
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsWarmth, redness, or tingly feeling under your skin, headache, back pain, nausea.
Useful Linkhttp://www.rxlist.com/fortical-drug.htm
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 9
(9) Primary information
ID1106
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameMiacalcin
CompanyNovartis
Brand DiscriptionMiacalcin Injection is a synthetic polypeptide of 32 amino acids in the same linear sequence that is found in calcitonin of salmon origin.
Prescribed forMiacalcin Nasal Spray is used to treat osteoporosis in women who have been in menopause for at least 5 years. To be supplemented with adequate calcium and vitamin D intake.
Chemical NameN.A.
FormulationEach milliliter contains calcitonin-salmon 200 I.U., acetic acid, USP, 2.25 mg; phenol, USP, 5.0 mg; sodium acetate trihydrate, USP, 2.0 mg; sodium chloride, USP, 7.5 mg; water for injection, USP, qs to 1.0 mL
Physcial AppearanceSolution
Route of AdministrationSubcutaneous or intramuSubcutaneousular Injection
Recommended DosageFor treatment of symptomatic Paget's disease of bone, 100 International Units (0.5 mL) per day administered subcutaneously or intramuscularly and for early treatment of hypercalcemia, 4 International Units/kg body weight every 12 hours by subcutaneous or
ContraindicationAllergic, nasal or sinus problem such as nasal deformities, a chronic infection, or nasal pain.
Side EffectsTremors or shaking, feeling like you might pass out, severe nasal irritation.
Useful Linkhttp://www.rxlist.com/miacalcin-drug.htm
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 10
(10) Primary information
ID1107
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsBleeding from your nose, runny or stuffy nose, dryness, itching, tenderness, or general discomfort of your nose.
Useful Linkhttp://www.drugs.com/miacalcin.html
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 11
(11) Primary information
ID1108
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsCrusting, scabs, or sores inside your nose, redness in or around your nose.
Useful Linkhttp://www.drugs.com/dosage/miacalcin.html
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)


Entry 12
(12) Primary information
ID1109
ThPP IDTh1014
Therapeutic Peptide/Protein NameSalmon Calcitonin
SequenceCSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP view full sequnce in fasta
Functional ClassificationIb
Molecular Weight3431.853
Chemical FormulaC145H240N44O48S2
Isoelectric Point8.86
Hydrophobicity-0.537
Melting Point (℃)N.A.
Half Life0.83-1.33 hours
DescriptionSynthetic peptide of 32 residues, formulated as a nasal spray.
Indication/DiseaseUsed for the treatment of post-menopausal osteoporosis.
PharmacodynamicsCalcitonin inhibits bone removal by osteoclasts and promotes bone formation by osteoblasts, leading to a net increase in bone mass. Calcitonin also reduces plasma calcium levels and enhances secretion of ions in the kidney.
Mechanism of ActionCalcitonin binds to the calcitonin receptor, found mainly in osteoclasts which then enhances the production of vitamin D producing enzymes (25-hydroxyvitamine D-24-hydroxylase), leading to greater calcium retention and enhanced bone density. Binding of calcitonin to its receptor also activates adenylyl cyclase and the phosphatidyl-inositol-calcium pathway.
ToxicityIt is devoid of embryotoxic, teratogenic and mutagenic potential.
MetabolismPrimarily and almost exclusively degraded in the kidneys, forming pharmacologically inactive fragments of the molecule.
AbsorptionRapidly absorbed and eliminated. Bioavailability is high following subcutaneous and intramuscular injection in humans and similar for the two routes of administration (71% and 66%, respectively).
Volume of DistributionN.A.
ClearanceStudies with injectable calcitonin show increase in the excretion of filtered calcium, phosphate, and sodium by decreasing their tubular reabsorption in the kidney.
CategoriesN.A.
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsWarmth, redness, or tingly feeling under your skin, headache, back pain, nausea.
Useful Linkhttp://www.webmd.com/drugs/2/drug-14128/miacalcin-nasl/details
PubMed ID25860966, 24708057, 24357414, 24252061, 22001608, 20946924, 18704953, 18023905, 17207880
3-D StructureTh1014 (View) or (Download)